Mylan announced today that its US subsidiary will release the first generic version of their EpiPen® Auto-Injector at a price of $300 per package, more than 50% less than their original product.
After last week’s controversy surrounding the 400% increase in the cost of this life-saving medication, Mylan expects to launch the generic version in several weeks. This cheaper version will be available in both 0.15-mg and 0.30-mg doses. However, Mylan will still continue to advertise and distribute their original EpiPen® branded product.
Mylan intends to continue running their patient assistance program and distributing $300 savings cards to eligible patients in an effort to maximize affordability to the widest patient population possible. Additionally, the company aims to start a direct ship program and increase access to epinephrine auto-injectors by way of federal and private insurance preventive drug lists, all in an attempt to lower or eliminate patient copayments.
The pharmaceutical company continues to express much interest in and commitment to meeting the needs of the underserved patient population by investing in education and awareness about anaphylaxis and providing epinephrine auto-injectors at an affordable cost.
Today, Mylan CEO Heather Bresch commented, “Generic drugs have a long proven track record of delivering significant savings to both patients and the overall healthcare system. The launch of a generic EpiPen®, which follows the steps we took last week on the brand to immediately reduce patients’ out-of-pocket costs, will offer a long-term solution to further reduce costs and ease the burden and complexity of the process on the patient.”
Mylan to launch first generic to EpiPen® Auto-Injector at a list price of $300 per two-pack carton, a more than 50% discount to the brand product [press release]. Canonsburg, PA: Mylan Pharmaceuticals; August 29, 2016.